Last reviewed · How we verify
CroFab — Competitive Intelligence Brief
marketed
Antivenom (polyclonal antibody fragments)
Crotalid venom toxins (phospholipase A2, serine proteases, metalloproteinases)
Toxicology / Emergency Medicine
Biologic
Live · refreshed every 30 min
Target snapshot
CroFab (CroFab) — Instituto Bioclon S.A. de C.V.. CroFab is a polyclonal antivenom that binds and neutralizes venom toxins from North American crotalid snakes (rattlesnakes, cottonmouths, and copperheads).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CroFab TARGET | CroFab | Instituto Bioclon S.A. de C.V. | marketed | Antivenom (polyclonal antibody fragments) | Crotalid venom toxins (phospholipase A2, serine proteases, metalloproteinases) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Antivenom (polyclonal antibody fragments) class)
- Instituto Bioclon S.A. de C.V. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CroFab CI watch — RSS
- CroFab CI watch — Atom
- CroFab CI watch — JSON
- CroFab alone — RSS
- Whole Antivenom (polyclonal antibody fragments) class — RSS
Cite this brief
Drug Landscape (2026). CroFab — Competitive Intelligence Brief. https://druglandscape.com/ci/crofab. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab